500 tables processed...
1000 tables processed...
1500 tables processed...
2000 tables processed...
2500 tables processed...
3000 tables processed...
3500 tables processed...
4000 tables processed...
4500 tables processed...
5000 tables processed...
5500 tables processed...
6000 tables processed...
6500 tables processed...
7000 tables processed...
7500 tables processed...
8000 tables processed...
8500 tables processed...
9000 tables processed...
9500 tables processed...
10000 tables processed...
10500 tables processed...
11000 tables processed...
11500 tables processed...
12000 tables processed...
12500 tables processed...
13000 tables processed...
13500 tables processed...
14000 tables processed...
14500 tables processed...
15000 tables processed...
5 iterations done
10 iterations done
15 iterations done
20 iterations done
25 iterations done
30 iterations done
35 iterations done
40 iterations done
45 iterations done
50 iterations done
55 iterations done
60 iterations done
65 iterations done
70 iterations done
75 iterations done
80 iterations done
85 iterations done
90 iterations done
95 iterations done
100 iterations done
Type 0 (140): Affymetrix HG-133A+B| ANKRD12 (low/high)| (Bind to mIL-1RAcP)| mDia2 IQGAP1 (yeast)| CML t(9;22) Resistant| Oral Cavity (T3N0M0)| SIRT1? ENaC ?-subunit| AZD6244 (MEK inhibitor)| GM-CSF/IL-3 ?c receptor| PI3K-mTOR inhibitor| 
Type 1 (2304): 125.8| 95.13| 95.67| 34.27| 34.18| 58.19| 58.23| 58.39| 34.68| 34.52| 
Type 2 (567): Netherland| Poxviridae| Colorectum| Invitrogen| Ependymoma| Fibroblast| Leukocytes| Oxysterols| Irinotecan| Epithelium| 
Type 3 (298): Regulation of biological quality| Expression of epithelial markers| Involved in alternative splicing| Increased likelihood of relapse| Retinoic acid metabolic process| Adjusted effect on cancer subtype| T cell receptor signaling pathway| Toll receptor signaling pathway| Time of recurrence-free survival| Genes overexpressed in leukemia| 
Type 4 (231): Costa et al. ( 2011 )| Hayes et al. [ 128 ]| Danza et al. ( 217 )| Zhang et al. ( 24 )| Zhang et al. [ 56 ]| Cohen et al. [ 67 ]| Braun et al. [ 35 ]| Cohen et al. [ 58 ]| Sheng et al. [ 74 ]| Wong et al. [ 81 ]| 
Type 5 (111): 5?-UUCUCCGAACGUGUCACGUTT-3?| 5?-AGGUGACACGUUCGGAGAATT-3?| 5?-ACGUGACACGUUCGGAGAATT-3?| 5'-TGGCTGACCTAAAGCCACCTC-3'| 5?-CATCTCTGCCCCCTCTGCTGA-3?| 5'-CGGACTCATCGTACTCCTGCT-3'| 5'-ATGGTGGTGAAGACGCCAGTA-3'| 5'?AAGCCTGTAGCCCACGTCGTA?3'| 5?-GGATGACCTTGCCCACAGCCT-3?| 5'-GGTGGCAATGGAGTAGGCGAT-3'| 
Type 6 (98): 3? UACGGG AAAAU UGU AACGUGA C| GTT CGC GTG GCG TAA GAG TAC| GCA TAA TGG GAA ACC GTG TAG| TTG CTC AGA ACT TAT ACC ACG| CAA TAG TGA TGA CCT GGC CGT| CTT CTT GCA CAC CAT CTC GTT| GTT TGG GGC ACA ACA CGT CAG| 3? CGACUCUCACAUCCU ACAAAUG U| 5' CGTGCTCGATGGGGTACTTCAG 3'| 5' TTCACGGTTGGCCTTAGGGTTC 3'| 
Type 7 (381): down Myc Pc-| Pekow et al.| Wong et al.| Zhou et al.| Dong et al.| Ajani et al| Unknown Tag| Tubulin, ?3| Guinea pig| Dental sac| 
Type 8 (389): Gingko biloba| Paired domain| Single center| Palmar fascia| Tongue cancer| Animal models| Whole embryo| Other tumors| Tumor tissue| Nuclear lumen| 
Type 9 (36): tgctcatgagttttccctggt| caccaccttcttgatgtcatc| ggccatagaactgatgagagg| ccacgctcttctgtctactga| ggctatccagcgtactccaa| ggcccaacatcacaagaaac| ctccttacccaggtcctgct| ggatgctctccaggtttgtt| gcagctgcagcagttccaga| agctccaaaggcagagacaa| 
Type 10 (83): Brown et al. (1994) [22]| T820fs*7 and P1439fd*34 ( n =1)| Ser339 (2 H bonds), Val335| PDCD6 (Park et al., 2012) [70]| Caspase -3 (Asp175)# 8120| CNS 2/2 Prostate 3/3 Lung 2/2| Ie Sage 2007 [70] , Fornari 2008 [81]| Currie et al . [ 44 ] (2012)| OSCC (162 out of 215 cases)| PR in 7 pts (21%) SD in 20 pts (59%)| 
Type 11 (211): Ligand for DAF-2| LVW/BW ratio, mg/g| JGI (Assembly V2)| Gst-Rack1 +, AmpR| low GM-CSF, 6 days| Withaferin A (WFA)| ?Hdm2 nucleus MQS| Neuropilin NRP-2| Incident AC (% CLO)| Egfr f24 FSC clone| 
Type 12 (2): TRGC2///TRGV9///LOC442532///LOC442670///TARP| FOSL2.PLB1..chr2.28628327.28860856_AMP| 
Type 13 (1072): ?2592.27| ?1.26722| ?7.99424| 12.7–167| 0.894588| 4284.108| 1.680151| 0.311877| 2.141034| 33560.67| 
Type 14 (76): Merrimack Pharmaceuticals and sanofi-aventis| Ipilimumab after adjuvant chemoradiation| Embryonic lethality, ? due to erythrocytosis| Native albumin and probably modified-albumin| Abdominal pain, fatigue and thrombocytopenia| Neurotoxicity, fatigue and thrombocytopenia| Trimethyllysine dioxygenase, mitochondrial| Required for actin cytoskeleton organization.| ?Lost for follow-up or missing tissue-samples| Cytochrome c oxidase subunit 5B, mitochondria| 
Type 15 (309): CGATCCACACGGAGTACTTG| CTTGGCTTGAGCTCCGAGAA| CTGGTTGATCCTGCCAGTAG| GTAACCCGTTGAACCCCATT| AGAACATCATCCCAGCCTCC| GCCGCACCCACCCTGTTCTC| CTCCCCCATTTGTTCCATGT| GATCAGCTCGGGCACTTTAG| ACCGCTGTGGCTCATCATCA| CTTCCATCGTCTCATTCCGT| 
Type 16 (13): CGTCTGTTGTGGCCAAAGCAGCAGGTTTTCTTCCACGAC| AACCAACGATTTAAAAGCTACAGTTTCTGTACTTTATTG| ACTGAACCTGACCGTACATACATGGACATCTTCTGCAC| 6FAM-ACCACCACCCAACACACAATAACAAACACA-TAMR| CGAGCTCAAGCTTCGAATTCTGATGTTTCGTAAAGCAACCAGG| CCTGGTTGCTTTACGAAACATCAGAATTCGAAGCTTGAGCTCG| 5?-CCTTTGGGAGAGCGGCCAAAGCCCTATTCACCTCG-3?| CAGCAGTATCGACTGGATAAAGTCAGTGCAAATGT| CCCTCGAGTTACGTCGGGGTGCCCACCAGTCCCGC| AATAGAATTCGATATGCTTATAGAAATAGTTGTG| 
Type 17 (1048): Fabp5| Abcf2| Ireb2| Htr2b| Oasl2| Irgm1| Akap6| Sirt7| Tgfb1| Dauv1| 
Type 18 (433): NCT01288430| NCT00433576| NCT01689870| NCT01449058| IPI00231689| NCT01824901| NCT02142803| NCT00142467| NCT01021748| NCT00265824| 
Type 19 (1085): 1?:?50| n?=?19| 10 ? 5| 10 ± 2| 10 ± 6| 90 ± 4| 30 ± 9| 30 ± 2| 1 ? 42| 50 - 52| 
Type 20 (50): Tumor markers: CEA, CA 19-9, TPS, TAG-72| Zhou et al, “OPTIMAL” 39 (Phase III)| ?pGEX-6P-3 Gpb1 (BamHI and NotI)| SEB (L45R, Y89A, Y94A)/ Cholera toxin| ELISA of plasma: CRP, IL-6, TNF-?, and IL-18| Examples: Xist, APOA1-AS, GLl1AS.| AMG 706 (VEGFR, PDGFR, c-Kit and Ret)| WERI Rb1 (HMGA2 siRNA Treated)| Age > 18 EGFR mutation + ECOG PS 0–2| Dominated by COL, FSIG + gFOBT| 
Type 21 (1098): 795 (220.1)| 209 (15.79)| 13.04 (3/23)| 20/73 (27.4)| 162 (81.0)| 489 (4.60)| 473 (0.83)| 129 (10.6)| 348 (22.0)| 167 (50.6)| 
Type 22 (2): atgactgaatataaacttgtggtagttggagctggtgXcgta| cgaagcttttatcttagtcttttatatttctttaataaag| 
Type 23 (132): Aqp3 , Aqp8 (only detectable at E15)| Survival rate at 2 years (95% CI)| CoQ10 (5 mM) and simvastatin (240 µM)| Published; Widemann et al. ( 112 )| Leung-Hagesteijn et al. 2013 [ 77 ]| No risk factors (>50% of all PTBs) 29| Microcephaly ( Sir et al., 2011 )| Oral C. difficile spores (140K) 4| 15 (12.3%) More common in exon 20 Lower RR| MM, multiple modalities‡, n = 539| 
Type 24 (296): Isocarboxazid| Dimethylation| Staurosporine| Amplification| Neuroblastoma| Ridaforolimus| Lipofectamine| Sphingomyelin| Rosiglitazone| Farnesylation| 
Type 25 (870): Afatinib| Melanoma| Diabetes| Squamous| Curcumin| Midbrain| Advanced| Bosentan| Knockout| Punctate| 
Type 26 (304): STK32B (mut)| T•8oxoA (CXC)| E1-E2 ATPase| KRAS [utr3]| API-5 Smad4| IGF-1 and IGF-2| C2-I, HopU1| MARK4/ Mark4| BSMV: TaRab7| pGEX-6P-3 Gpb1| 
Type 27 (434): Tempol versus saline| Protein copy number| GO biological process| Intracellular Domain| Increased drug efflux| Tumor necrosis factor| Dopaminergic neuron| Oncorhynchus mykiss| Humanized from mouse| Sham operation group| 
Type 28 (168): Delivers exocytic vesicles to plasma membrane| Details about receptor expression not provided| Zinc-finger nuclease to target steroid receptor| Transcription factor Tubby signaling pathways| Nerve growth factor receptor signaling pathway| Demehtylation of Histone or non-histone proteins| Increased risk of infections, including fungal| Rat mammary benign and malignant tumors induced| Relationship with elevated levels of insulin| Perfusion cells treated by retroviral vector| 
Type 29 (240): 0.65 (0.37 - 1.13)| 44 (16/36) rs = 0.63| ?6.65±0.16 ( n =10)| 5.80 (-1.12, 12.7)| ?6.69±0.12 ( n =10)| 18 (4.98 × 10?4)| y = -3.36x + 39.07| 1.481 (1.08 to 2.03)| 1.24 (0.52 to 2.95)| 92.6 ± 13.65 (45)| 
Type 30 (135): (ii) Suppresses differentiation| Amplification, overexpression| Protein amyloid A, transthyretin| Totiviridae /Leishmaniavirus| Hyperactive or overexpression| Synthesis of prostaglandins| Bone marrow, hypocellularity| Other congenital abnormalities| Uteroplacental insufficiency| Endocytosis, Transcriptional| 
Type 31 (853): -0.3886557| ?1.0159812| 4.25×10?15| 1.43–27.03| 28.36±0.12| 2.273±0.41| 23.10±5.28| 12.71±0.48| 20.96±1.46| 25.87±0.29| 
Type 32 (95): H446AR-shKCNJ2-2| U266/pcDNA3-AGO2| TAF1B/mKIAA1093| E6?151/Bmi1/hTERT| SB220025/rhIL-1RA| BEL7402/ADM+CsA| OE2:GLU533/H60| 293/WTH3RNAi-6| pGBT9-LPPL612A| MDA-MB-157+siTBX2| 
Type 33 (96): HCT116 cells p53+/+ without DNA damage| HCT116 cells p53?/?without DNA damage| band 3 Cl-/HCO3- exchanger, B3RP2 (aka Slc4a2)| 131I-TM601 (scorpion venom peptide), CC-8490| Slice culture (CA1 region at DIV9–11)| pERK1/2 Increased ? Others no change (PC12)| HCV-JFH1 (2a) infection/ Huh7 and Huh7.5-1| Human gastric SGC-7901, MKN-45 cell lines| Human Cdk2-Cyclin B1 complex (2JGZ)| Combretastatin A-1-Phosphate (OXi4503)| 
Type 34 (77): mTH ?2707/?2749 antisense| 252 patients 62 (18–85)| miR-182, miR-34a, miR-148b| miR-16, miR-34c, and miR-199a| Birinapant (TL32711)21| 18 studies (1984–2004)| Tipifarnib (R115777)| NCT01914484 (nilotinib)| rs13849381 (intron)| 1.09 (0.92–1.23, Additive)| 
Type 35 (92): Sydh_Ntd1_Znf274| GSE21909_Cortisol| Estradiol-9-N3-Ade| Ego3/Slm4/Nir1/Gse1| hsa-miR-574-3p_st| Intersectin/DAP160| RLS-Thr6-kallidin| ORF61/membralin| hsa-miR-1224-5p_st| miR–ephrin-A1–LNP| 
Type 36 (9): 5’-ttgttctcctacacacatagatagggtaa-3’| 5?-aaactcgagttatcgggtcatgggtgcca-3?| 5'-caactgggacgacatggagaagatctggca-3'| 5'-gaggatcttcatgaggtagtctgtcaggtc-3'| 5’-ctataaaaggggtgatataacgctctccaag-3’| 5’-cttggagagcgttatatcaccccttttatag-3’| ggttaattttagttagttatttattgggagtttt| tcaggtttactcaacgtcatccagcagag| 5’-tcagcataatacaaaatggactgc-3’| 
Type 37 (81): NEUROGENESIS| RLSKRPPGFTPFR| VLLAVSEEYLDLR| OSTEOBLASTIC| GVAPWGTTTCRRF| GOTERM_MF_FAT| EGFR/KRAS/BRAF| INTERPRO_NAME| TDDEMpTGpYVAT| RPPGFSPFRVD| 
Type 38 (11): www.clinicaltrials.gov/NCT00617890| rno-mir-181a-2//mir-181a-1(MSub)| 1–18:2-Lysophosphatidylglycerol| 20,22-epoxyeupha-24-ene-3-one| Cholest-5-en-3?,7?,25-triol| IPR017441:Protein_kinase_ATP_BS| age-1(lf);daf-18(lf);let-60(gf)| http://mint.bio.uniroma2.it/mint/| http://starbase.sysu.edu.cn/| Xanthobacter_autotrophicus_Py2| 
Type 39 (1219): 92 (9.0)| 33 (6.0)| 3 (6.8)| 2 (6.7)| 2 (4.3)| 3 (4.7)| 3 (4.6)| 7 (6.9)| 1 (4.3)| 1 (4.2)| 
Type 40 (115): Sucrase-isomaltase| Cortisol-producing| Anti-proliferation| Clathrin-dependent| Phospho-diesterase| Photomutagenicity| Belagenpumatucel-L| Tetrathiomolybdate| Phosphoglucomutase| molecular_function| 
Type 41 (1577): 2C| 2D| 3B| 3K| 4A| 4N| 4X| 5B| 5R| 6X| 
Type 42 (88): [ 14 - 16 , 24 , 34 ]| [ 68 , 387 – 396 ]| [ 14 , 106 , 145 ]| [ 149 , 190 , 191 ]| [ 35 , 36 , 37 , 45 ]| [ 12 , 13 , 26 , 27 ]| [ 34 , 123 , 124 ]| [ 21 , 151 , 159 ]| [ 135 , 564 , 582 ]| [ 226 , 227 , 228 ]| 
Type 43 (18): F:TTAAATGGTGCAACTCTG R:TGGATGGTACTAAGAAGAAC| F: CTGTTCGCGCTCTCGGCAG R: CCAGTAGCCACAGCAGCGG| F: TACCAGATCGCGCCCATCTA R: GATGGCCTCGATGCGCTTC| GGGTGGGAGGTGGGAGGG ATCCCCACTCTCCTATCTAAT| F: ACCAGATGCCCTACACTACC R: GTGCATAAATGGAGAGTGTG| F: CAACGTCATCTACCGTGACC R: AAATACTCCGGTGTCCCACA| F: ACCACAGTCCATGCCATCAC R: TCCACCACCCTGTTGCTGTA| CGCGGTGGCTGTCATCA AGGGTTGGGTCCCAGGAAT| For CTGTGTTCGTCTTTTCTTCC Rev TCATCCACTTTTGCCTTCT| GCGGTGTCGC P AAGACGCAAGACGCGGAGGCAG| 
Type 44 (222): Regulate transcriptional activity of Sp1| Complex with complete/partial loss of ch5| Loss of a putative PKC phosphorylation site| Epithelial layer of human bronchial organ| Congenital stationary night blindness, ASD| In vitro (human tracheal epithelial cells)| (2.2) With covalent modification of the lipid| Jackson Immunoresearch laboratories, Inc.| Maxillary diastema Mutants with 4 molars| Reversed the depleting effect on retinal GSH| 
Type 45 (20): R [1, 0, 1]+ E 2 ? R [1, 1, 1]     (50d)| R [0, 1, 1]+ E 1 ? R [1, 1, 1]     (49d)| R [1, 1, 0]+ E 3 ? R [1, 1, 1]     (51d)| z 7 = R [1, 1, 1]     (52h)| AL: [ 119 - 122 ] ?C: [ 120 - 122 ]| 10.7% ( n = 7) ?3.1% ( n = 2)| 62% ( n = 41) ?24.2% ( n = 16)| ?[ 207 , 208 ] or ?[ 209 ]| c1?=?69; c3?=?14; c4?=?50; c5?=?0.78| 95°C 30?s; 59°C 30?s; 72°C 30?s| 
Type 46 (20): TIRAP-MyD88-TRAFs-IKK?/?-NF-?B| Cyc-[PR(Me)GPR(Me)PVALKLALKLAL]| Reverse: 5?-AGGGACTTCCTGTAACAATGC-3?| Reverse: 5?-ATTGCCGATAGTGATGACCT-3?| 3?-Primer 5?-CCATCACAACCCCAAACATCA-3?| h- EF1 alpha 5?-TGCGGTTTTTGTCATCAAA-3?| Rev:5?-ACGGCCATCACCATACTAGC-3?| Reverse 5?-TCCTTGGAGGCCATGTAGGCCAT-3?| KHSRPILF3RANLin-28Lin-28BmLIN-41| Reverse 5’-TTGAGAGCAATGCCAGCC-3’| 
Type 47 (824): FBXO45| A8MVL5| Q9JIE3| Q9NVH6| SLC7A6| HROG13| HROG25| HROG36| HROG42| A8DYR6| 
Type 48 (85): TCF4, modENCODE [94]| (14) NF?B, STAT3, HIF-1?| YAP1_HUMAN; S109 or T110| SOD1-WT, A4V and G85R| pACYDuet- CDC10S46N - CDC11| Blood: IL-6, CRP – ELISA| 14-3-3 ?, HER2, EGFR, MAPK| GST-Lum + ALK5 ShRNAi (3)| ARR2Pb.Stat3C/ PTEN +/?| BCR-ABL-GFP+ N17 H-Ras| 
Type 49 (22): Rev: 5' TCCAGGCCCGTTTCGTTCACCTCGATACG 3'| OXIDATIVE STRESS REGULATING PROTEINS| 5?-CTTGCCTACG CCACCAGCTC CAGCTCCAAC TACC-3?| 5?-GGTAGTTGGA GCTGGAGCTG GTGGCGTAGG CAAG-3?| 5' - CGCTGGACCTGTGTGAACTGATGGGCCAGATC - 3'| Rev: 5' GCATCTCCTGCATTACCCTGATATCC 3'| 5' AACTCGAGGGTTTAAACTCAATGGTGATGGTG 3'| FAM-AGC TGG GCG GTG TAC GAA GTC G-TAMRA| FAM- 5?-TCGTCGCACATCGAGTCGGC-3? -BHQ| 3 ' - GAACTAAAGCGCCGC CACCAGGACGAAGAC-5 '| 
Type 50 (218): Agranulocyte adhesion and diapedesis| Biologically relevant and consistent| No improvement in neuropathy severity.| Normal cardiac function and morphology| Increased adiposity, Insulin resistance| Total number of annotated singletons| Earlier onset; possibly more aggressive| Osmoregulation Cell volume regulation| Platelets usually normal or increased| Possible tumour-suppressor functions| 
Type 51 (2184): 46.00| 10.20| 10.05| 0.028| 0.029| 0.023| 0.021| 0.026| 0.027| 0.024| 
Type 52 (162): siRNA for RSV (viral gene)| Etoposide ? c-PARP | Total| Two-component GAP Byr4| Arp2/3 complex; actin; VASP| Activated by E2F1 and MYC| EBNA-1, Epstein-barr virus| Upregulation of FOXD3| UNG activation 2 min, 50°C| Kabbinavar et al, “ATLAS” 32| U0126 or trametinib (MEK)| 
Type 53 (32): Tetra-allelicpolymorphisms| 1-deoxy-galactonojirimycin| Survival/neuroprotection| 2079 (unavailable/unavailable)| Cell growth/differentiation| Glycolysis/gluconeogenesis| Renin-angiotensin_system| http://simple.stanford.edu| Glioblastoma-multiforme| Up-regulation/down-regulation| 
Type 54 (243): Beclin 1 Lamp-2 mi-30a| Olivieri et al. (2014)| Imatinib 300 mg (1xd)| Carvalho et al. (2009)| Fedorova et al. (2008)| O?uztüzün et al. (2011)| Docetaxel 60 mg/m2| IC50 value (in mice)| S-180 ascitic tumor| Walters et al. (2014)| 
Type 55 (204): Irinotecan/5-FU e + cetuximab| ISG-15 protein conjugation| WBRT?+?sequential erlotinib| Diathermy (6Fr. cystotome)| ?Decreased AT2R synthesis| Gefitinib vs. Carbo/Taxol| Erb B-2 promoter/MUC1 enhancer| Identifying BRCA 1/2 mutation| (?) 120 min after inhalation| hMLH1 methylation* Iranian| 
Type 56 (1420): DHX9| XBP1| MCF7| BCL2| FPR2| MDH2| BDL5| MED6| MEG3| MEK1| 
Type 57 (123): Deleted in lymphocytic leukemia 7 ( DLEU7 )| Relative EZH2 expression (high vs low)| Cancer Genome Atlas Research Network ( 2011 )| Overall Median in Squamous cases (n = 182)| Cytoskeletal regulation by Rho GTPase (111)| Gemcitibine, Erlotinib vs. placebo [ 15 ]| Kdm2b lysine (K)-specific demethylase 2B| Regulator of G-protein signalling 16 ( RGS16 )| NADH dehydrogenase 1 beta subcomplex 6| Sh3bp5l //SH3 binding domain protein 5 like| 
Type 58 (207): Interferon regulatory factor 8 (IRF8)| ZBPF Zinc binding protein factors| Fc epsilon RI signaling pathway| FAS pathway and caspase network| Rhodopsin kinase (Visual cycle)| Family history of CVD or diabetes| Median Length of Stay in Hospital| DNA base excision repair defect| Access through Pathway Commons| Protein disulfide isomerase (PDI)| 
Type 59 (536): Gal3 mAb| CH2 ring| PR: 2 pts| Shh + Gdi2| Score 2+| miR-1 tg| Lung 1/9| Arg > His| Gly > Ser| TP53 mut| 
Type 60 (306): Non-genomic actions of E2| Bocchio-Chiavetto et al 180| Kinesin family member 2A| Hard filtering with no SW| Plasma membrane part (6)| Male Sprague-Dawley rats| Nitric oxide synthase 1| Erlotinib?+?gemcitabine?+?RT| TG-elicited peritoneal M?| Inhibitor of caspase 3| 
Type 61 (308): EWS-DDIT3| EGFR/CEP7| PGPD-BCY1| PDIA3_RAT| TR-LRF_Q2| ADAMTS-12| NI/TRIM13| EGFR/PI3K| ETS1/RUNX| G3P_HUMAN| 
Type 62 (676): 1.03±0.08| 0.34±0.09| 0.45±0.03| 0.45±0.10| 10.60±0.7| 0.64±0.02| 1.02±0.07| 1.02±0.09| 2.03±0.05| 0.35±0.06| 
Type 63 (13): interfly.med.harvard.edu/index.php| Pemetrexed+carboplatin+vandetanib| http://jjj.biochem.sun.ac.za/index.html| http://www.massmatrix.net/mm-cgi/home.py| Cetuximab/Capecitabine/Oxaliplatin| http://genie.weizmann.ac.il/pubs/mir07/| http://GenetMed.fudan.edu.cn/dbHCCvar| Cephalosporin-mustard-carbamate| magnesium-dependentphosphatase-1| Steroids/Tacrolimus/MMF/Basiliximab| 
Type 64 (122): RPL32; NM_172086| ZNF598 (Q86UK7)| PDHA1 (AW057819)| MCP-16? ?2518A/G| KLF17 (Q5JT82)| F38A6.3d (HIF-1d)| DLAT (BF978872)| 2PRT A (318-438)| cTNF-RI aa 206–426| C14B1.4 (WDR-5.1)| 
Type 65 (1128): 7.4 ± 0.42| 1.9?±?0.44| 1.7 ± 0.16| 2.5 ± 0.62| 2.3?±?0.13| 4.3?±?0.48| 1.88 ± 0.61| 1.13?±?0.99| 5.15?±?0.14| 3.85 ± 0.35| 
Type 66 (408): [ 96 , 110 ]| [ 80 , 121 ]| [ 15 , 27 ]| ( 37 , 86 )| [ 72 , 83 ]| [ 29 , 73 ]| [ 7 , 148 ]| ( 28 – 37 )| [ 59 – 61 ]| [ 49 , 50 ]| 
Type 67 (267): Slow Half-Life| TGF-?1 receptor| tRNA exportin| PI3K inhibitor| IL-6 induction| HER2 positive| IHC antibody| m-TOR inhibitor| 'miRNA sponges'| CRC, resection| 
Type 68 (299): Next generation sequencing| Hyperactive and hypoactive| Cellular energy metabolism| Infiltration of leukocytes| G protein-coupled receptors| Proximal tubular epithelial| Estimated unique transcript| Manufacturing of pesticides| Carboplatin plus paclitaxel| Tans promptly and intensely| 
Type 69 (178): Nucleo +Cytoplasm| N/A: not applicable| TGF-beta signalling| Early (shrinkage)| Graft Dysfuncion| GluK4 expression| miRNA regulation| MDS, not classified| Nuclear / Cytoplasm| Anti-PD-L1 antibodies| 
Type 70 (18): [Swiss Prot:ANXA2_HUMAN]| uPA-Nox1/Nox4; PDGF-Nox1-cofilin| [Swiss Prot:HNRPD_HUMAN]| MAT? ras1::ade2+pG7RAS1-NAT| BzATP, ATP, UTP, or ??-Methylene-ATP| ARID1A PIK3CA IL-6 overexpression| TDGF1/CRIPTO overexpression| Genes up-regulated in (ESC+IPSC+EGC+ECC)| FRTL5 (RET-PTC1)+pSilenc-TTF1| (egfsignal + PI3K)/2–0.3.*MAPK| 
Type 71 (141): De Brouwer et al. ( 2012 )| Roberson et al. ( 2011 )| Juergens et al. ( 2011 )| Robinson et al. ( 2013 )| Ludovini et al. ( 2011 )| Grainger et al . [ 105 ]| Bexfield et al. [ 145 ]| Rosenberg et al. ( 2012 )| Houghton et al. ( 2012c )| ( Nazarian et al. , 2010 )| 
Type 72 (40): HEVPRS*PDDAKVVDLFK| IQNTGDY(pY)DLYGGEK| ITLCIAVSNCCFDPIVYYF| EGFR_HUMAN/PTN6_HUMAN| NUCLEAR_RECEPTORS| IGEHYVHVNATYVNVKCVA| PID-PI3KPLCTRKPATHWAY| R.QNLIPYNFIDDVIR.T| LEE_BMP2_TARGETS_DN| PROTEASES/PEPTIDASES| 
Type 73 (396): eIF4E O/E| THBS1 -M| CDB1 IgG| ?UM-SCC 33| ACE I/D2| M CD8A R2| CDC25A Rv| OVCAR 10| COP-I ?1| CALM1 IL6| 
Type 74 (64): CTCAACTACATGGTCTACATGTTCCA| AGAGGATCCATGCAAATGGACGTACG| CAATTGCACTGGATACGACAAAATATG| UGGUCAACGUGGACAUGAACGACAUAG| AAAAGTTTCCATTTTTTGGTGAGTAGA| GTTATGAGCCAAACCTGTCAAATACTC| GGAGCCCTTGCGGGGCCGGCCCTTGCG| CAACACCCTGGCCGAGTTGGTTCAT| TCAGTGCCTTCGGACTGTCTATTTG| CCGGAGUGGCAUCUCAACUCGGAUU| 
Type 75 (29): DVL3; LATS1; FZD4; TP73; TCF7L2| ATG5; ATG7; ATG12; MAP1LC3B; BECN1| RA/RARS (37) RAEB/RAEB-t (51) CMML (11)| (iii) PRKCB* : HIST1H3I : CUL4A : CUL1| MKT1 (BY): IRA2 (RM): SWH1 (RM)| PPAR-?, p53, CHOP-10, CREB, CRE-BP2| G-CSF TNF-? VCAM-1 MIP-2| ? NEFL GABRA1 SYT1 SLC12A5| BDNF-IgG (OX26); NGF-IgG; GDNF-Tat| WFDC8 (3), SLPI (1), WFDC5 (1), KAL1 (1)| 
Type 76 (266): has-miR-384| hsa-miR-762| hsa-miR-432| hsa-miR-429| hsa-miR-598| age-miR-508| hsa-miR-130| hsa-miR-433| hsa-miR-494| hsa-miR-585| 
Type 77 (35): NM_022481 ; NP_071926 (1544aa)| ERK1/2 (T202/Y204. T185/Y187)| MTHFRC677T , MTRR (rs1801394, rs162049, rs10380)| CD63 FLJ20559 GP2 AB065858| BMS-936559, MSB0010718C, MPDL3280A| TPR?80 & TPR?74,91 and ISR70,74,97| P2 (MEK1 siRNA-7811 + MEK2 siRNA-914)| OR: 6.04, 95% CI: 1.89–19.36| aa 726–926 (ROCK I), aa 698–957 (ROCK II)| EST Cyclin D2 (Mm.333406, BQ445605)| 
Type 78 (287): ?Unilateral duplex ureter| Increased in tumor tissue| Increased ischemic injury| Atypical medullary cancer| Asphyxial cardiac arrest| Thyroid papillary cancer| Mouse embryonic stem cells| In vitro endothelial cells| Number of metastatic sites| Mouse epiblast stem cells| 
Type 79 (406): Epigenetic regulation| Quadrupole resolution| In atropic endometrium| Tyrosine hydroxylase| Chromatin regulation| Prolidase deficiency| Pulmonary metastasis| Inducible conditional| Structure undisclosed| Proteasome inhibitors| 
Type 80 (421): 38.7 ± 10.2 #| (575.0 17 ) b| 5.91±0.22 ? M| 6.13±0.14 ? M| 29 (31.5 %)| 2.559 e ? 03| 4.98±0.12 *| 7.95±0.61 *| 18.17 +/? 2.0| 58.3±0.79 ##| 
Type 81 (292): Tan et al. (2011)| Xie et al. (2011)| Introns 27-38| Partial5 [36]| Up(1.67 fold)| ?Positive (27)| Headache (14%)| Virginia #29046| Cui et al (2003)| Zhu et al. (2011)| 
Type 82 (420): Astacin protease| Pleural effusion| Grifola frondosa| Choline chloride| Unknown function| Unknown receptor| Hydrogen peroxide| Imatinib mesylate| Suicidal ideation| Fasciola hepatica| 
Type 83 (475): 4.36 (1.73–11.00)| 6.95 (0.02-35.65)| 6.81 (2.21–21.00)| 226.0 [95.5–568.0]| 1.88 (0.28–12.59)| 1.44 (0.82–2.55)| 1.18 (0.34–4.17)| 76.1 (67.4–86.0)| 1.16 (1.04–1.28)| 1.28 (0.86–1.89)| 
Type 84 (30): photolyase, 3e-13, (BAA12067.1)| Eur J Med Chem. 2011;46:1245-53| Neuronatin (Mm.233903, NM_010923)| Syntaxin 1A brain (Mm.6225, NM_016801)| Liu et al., FEBS Letter, 2010 584(5):911-916| arf-1.1(ok1840); lin-2(e1309)| ZR75-1, BT474 (orthotopic)| Vatalanib (PTK787/ZK222584)| EGFR -E746_T751del, I ins/S752_I759del| rab-7(ok511) ; let-60(n1876)| 
Type 85 (59): HSPB6, SLIT2, CPXM2, EFEMP1, CHODL| CHEK1, CDC2, SERPINE1, STEAP3, CCNE2| ADAMTS8, MMEL1, TIMP3 , TLL1, USP46| GMFB, AGAP2, CCNE2, MOBKL1A, PKIB| INADL, NRK, ODZ2, PPAP2C, RAB21, RLIM| CCNB2, CDK1, CKS1B, WEE1, YWHAZ| BST2, DGKG, GAS1, PDCD4, TGFBR3, VEZF1| SGMS1, PTEN, ALOX12, PRKAG3, PLCD4| NFKB1, PTGS2, NOS2, VEGF, AKT, ERK| ZNF, PVRL2, LASS4, BCL2, CLDN, FGF| 
Type 86 (307): Low expression RB1| ?High versus low| Median follow up| Munich-Wistar rat| forkhead box M1| 11 with advanced PC| ap-Gal wing disc| Atorvastatin 10 mg| Phase II single arm| Ion homeostasis (4)| 
Type 87 (59): chr9:99086401–99122485| chr9:22010493-22055620| 23.51(0.01-157.42)c| chr9:21967751-21994490| chr20:61759606-61798050| chr7: 73605528-73605624| 6.4206e3–8.9995e6| chr19:11170839_T_C| NM_005204.2-2809s1c1| 140069236–140083057| 
Type 88 (4): GR212046GR212052GR212105GR212131| AJ927925AJ927897AJ927925AJ927925| NT_034772.6(22829799-22829407)| 14967450,16680569,11349215,11344033| 
Type 89 (25): R: 5?-TATAAACAACATCTTTCACCCTTACCT-3?| 5'-GGCAGGAGGCAGACGUUGGCAGUGGCA-3'| 5?-AGTCGCCAAGCGCAAGAGATCAGCGCC-3?| 5?-GAAATCGGAGATCAGAGGCCCGGACAGC-3?| 5?-(GC40)CCGCTTCTTGTCCTGCTTGCTT-3?| (FAM)-GGCGCCTGGTCACCAGGGCTGCTTT| 5?-ATCTCAAATTGACGGAGTAAAAGGACAAT-3?| 5?-ATTTCGGGAATGCTGAGAAAACAGACAGA-3?| 5?-ATTGTCCTTTTACTCCGTCAATTTGAGAT-3?| REACTOME_SEMAPHORIN_INTERACTIONS| 
Type 90 (2673): 37.7| 11.5| 11.4| 11.3| 11.2| 11.8| 11.6| 38.3| 12.2| 12.1| 
Type 91 (48): v1.10880; v1.15709; v1.12348| v1.08207; v1.16237; v1.14824| 24917133 - 25116350| 24 (14.8) 21 (12.9) 45 (27.6)| 30361298 - 30787250| 9262 12.72 10.25 to 10.13| 165.1 (103.4, 289.2)| 93 (32.2)/196 (67.8)| 36,476,724 (81.93%)| (17658464); (17008542)| 
Type 92 (117): High CD63 (n?=?81)| Late DOWN (n = 29)| GC for PAR-2 [ 57 ]| SP Diet ?6.4?±?0.9| SP Diet ?3.3?±?0.5| PD (40), Cont (38)| 14% of inv(16) AML| ? TMT 8-plex 1+2+3| pHER2 Group 3+ (16)| 51 GKRS alone = 32| 
Type 93 (167): FOXP1, CCN8, HOXA1| MIF, PRAME, GGT1| SMAD7, SMAD6, TGFB3| VEGFR1-3, EGFR, RET| EFHA2, ST18, ACACB| GATA6 MIB1 RIOK3| MEK, ERK, EGFR, HER-2| OVA + siRNA SOCS3| FGFR2, FGFR3, TCF4| ACTG1*, TUBB, TUBA1B| 
Type 94 (1346): 5.39E-05| 4.48E-02| 2.43E-02| 2.19E-02| 1.99E-05| 1.88E-04| 7.57E-03| 3.11E-02| 7.22E-05| 4.24E-06| 
Type 95 (120): RAB7B, member RAS oncogene family| RAB5A, member RAS oncogene family| Zeaxanthin epoxidase (ZEP, ABA1)| SMEK Homolog 2, Suppressor Of Mek1| RAB10, member RAS oncogene family| Hyperactivation of PI3K and MEK| Transition from BFU-E to CFU-E stage| Affymetrix HG-U95 Version 2 Array| Ribonuclease P/MRP 14?kDa subunit| Dana-Farber Cancer Institute, MA, USA| 
Type 96 (13): [ 231 , 249 , 250 , 251 , 252 , 253 , 261 ]| [ 47 , 49 , 147 , 178 , 213 – 219 ]| IL28B [ 230 , 232 , 233 , 238 , 289 ]| [ 102 , 167 , 172 , 280 – 282 , 296 – 298 ]| [ 245 , 251 , 252 , 253 , 254 , 255 , 256 ]| [ 142 , 148 , 149 , 155 , 156 ]| [ 257 , 255 , 256 , 259 - 258 ]| 33 , 164 , 165 166 31 167 67 209 210| 3, 5, 7, 8, 17, 19, 24*, 32, 34, 35, 36, 37| FGF-1, 2, 4, 6, 8, 9, 16, 17, 18, and 19| 
Type 97 (203): ??Pituitary tumor-transforming 1| Epididymal secretory protein E1| Regression factor for Component 5| Myosin regulatory light chain 2| Early growth response protein 1| chromosome X open reading frame 57| Estimate of accelerated aging *| Ubiquitin specific peptidase 10| Zinc finger E-box binding homeobox 2| sorbin and SH3 domain containing 2| 
Type 98 (1): acagcagguc a agaagaguauagugccaugcgggaccagu| 
Type 99 (163): Cell cycle_G1-S Growth factor regulation| ?IGF1R in patholgical tumor progression| Upregulation of PI3K (might be possible)| Hs histone H2A variant Barr-body deficient| Breast cancer (HER2-amplified metastatic)| Everolimus + octreotide LAR + Bevacizumab| Proteosome Subunit macropain alpha (PSMA-1)| May promote DNA damage-induced responses| Expressed in LPS-stimulated macrophages| WAT (trans-) differentiation, BAT activation| 
Starting to cluster headers....
500 tables processed...
1000 tables processed...
1500 tables processed...
2000 tables processed...
2500 tables processed...
3000 tables processed...
3500 tables processed...
4000 tables processed...
4500 tables processed...
5000 tables processed...
5500 tables processed...
6000 tables processed...
6500 tables processed...
7000 tables processed...
7500 tables processed...
8000 tables processed...
8500 tables processed...
9000 tables processed...
9500 tables processed...
10000 tables processed...
10500 tables processed...
11000 tables processed...
11500 tables processed...
12000 tables processed...
12500 tables processed...
13000 tables processed...
13500 tables processed...
14000 tables processed...
14500 tables processed...
15000 tables processed...
5 iterations done
10 iterations done
15 iterations done
20 iterations done
25 iterations done
30 iterations done
35 iterations done
40 iterations done
45 iterations done
50 iterations done
55 iterations done
60 iterations done
65 iterations done
70 iterations done
75 iterations done
80 iterations done
85 iterations done
90 iterations done
95 iterations done
100 iterations done
Type 0 (5164): Charge| c-Met| Peps| No. of genes in pathway| BAC number| Chrom.| Pediatric| Intervention goal: ERK?=?1, PI3K?=?0| VPCs INDUCED, %| Germline mutation| 
Type 1 (173): ALT (U/L)| CKD| Phase III 6 Ipi and DTIC (Ipi at 10 mg/kg) 250| CRF| cryo solution| Case 13| OD| G0/G1 population (% ± S.D.) *| VEGFR/ACTB| Trabecular thickness (?m)| 
Type 2 (376): Other tissues affected| Body fluid| FXFP motif| C. elegans homolog| Site(s) with the consensus PX(S/T)P sequence| Chromatin State at TSS| Human gene| gene:| Arf| Oncoproteins involved in DDR| 
Type 3 (402): Mc(Hs)| Total number of fragments| 95% Confidence Interval of Hazard ratio| Ad-36 positive| WT-CTRL (n?=?6)| Percent of S cells (SD) *| % G2/M| Diet-induced obese rats (DIO)| Particle Associated HIV (248)| Reference ranges| 
Type 4 (207): 1990–2008| Probe IDs| D 0| Vehicle ( in vivo )| ABW ( n  = 12)| MTT (OD value)| LH (ng/ml) N.S.| 1w| WCC(x109/L)| FPAs| 
Type 5 (305): Event frequency, (%)| SOD (U/mg protein)| 1O2G(%)| Milk fat percentage1 (×100)| CLP| rs17849071G/T, n/N (%)| C. sinensis sequences (%) a| Promoter sequence| Sperm count a| KRAS mutated, n (%)| 
Type 6 (24): Reverse primer 5??3?| Reverse primer sequence (5????3?)| Antisense primer| Probe (5?-3?)| Telomeric repeat| Primer Forward (5'-->3')| Primer sequence : (5?-3?)| Repeat| Forward primer sequences (5????3?)| Oligo sequence 5'-3'| 
Type 7 (306): Differentiating group| Core and clock-related genes| Biopsy origin| Reported protein interactions from Pepcyber| JIA-associated genes with correlated expression data that lie within the minimal essential network (MEN)| Naturally presented by SSX+ tumor cells| In vitro (cell type)| Translocated Genes| ChIP| Yeast gene(s) a| 
Type 8 (394): Swiss-Prot hit| Effect of somatic mutation| Country/ethnic group| Tumor localization| Country Loa Acquired| Strain or plasmid| Df (3R) Tl-x| Time Sample Acquired| Tool name| CD| 
Type 9 (545): CDDP IC 50 (?M)| EXPRESSION OF miRNAS/mRNA IN PRIMARY RB TUMOURS| % of annotated| % genes| Cover percent (%)| Fold change CSCC| KRAS c12/13| In combination with LSM| Path| Fold change (log2) a| 
Type 10 (41): Potential genes| Gene (Location)| gem1? strain containing pRS416 plus:| Oocyte and Blastocyst| Reference (EGFR)| Protein /Epitope| A. testudineus| MHC Restriction| Cell Line Group| Trial Reference Number| 
Type 11 (60): CKA| KA| Methylated sugars| probe set| Database entry| Best Hits with miRNAs in miRBase| Unigene_ID| Nanomaterials| Gene Model *| Target miRNA| 
Type 12 (194): Acute GVHD| Inhibitor (company) commercial name| Current use| Clinical development stage| Testing stage a| Given| 5 ?M| RAR?2 region| List of primers| Bacterial factors| 
Type 13 (87): ?log ( P value)| Apc| Lon protein expression| A1C (%)| Click Beetle Green (Cratomorphus distinctus)| Epac| Malignant breast epithelium| H2O| A800 + A779| Wildtype Diabetes| 
Type 14 (158): Cell of origin| Expression levels in GC tissues| Dir| Role of autophagy| Macrolide| miR-34| Homolog definition| Modification of Smad7| Relevant histological subtypes| Deregulation| 
Type 15 (268): Dose (mmol/kg)| Ad5| Clone #| GenBank #| SHANK3| Gene_id| 3w| BH| UNIGENE ID| Sequence number| 
Type 16 (502): Proposed binding site residue| myrArf1| Number of cells screened per selection| GeneBank Accession / SwissProt Accession| Plasma or Sera| Number of patients/recurrence/death| Day 8 Notch OFF versus Day 5| Fold log(AD/N)| Class II| Mass (Da)| 
Type 17 (568): shNOX1 regulation (2DE)| Controls ( n ?=?114)| CD44s (% of cells)| IC50 (µM) (with AZI)| K 1 (?M ? 1 S ? 1 )| NIS| Univariatea)| Multiple regression| IC 50 (n)| PC346Flu2| 
Type 18 (64): C/C| CEU| LI| EXP| Fold Change in hnRNP E1 binding| Viable cells (% of control)| Polymorphisms| UnperturbedTCR pathway| e2f-1 [case (%)]| Carbachol (1 mM)| 
Type 19 (100): Translocations| Control ( n = 32)| OS mt KRAS: control vs. EGFRI (Hazard ratio)| 8?hr reperfusion| Mgat5?/?| Frequency of missense mutations in breast cancer (# most frequent in breast cancer); in other tumors (# most frequent)| Type I| Frequency (FD) a and level of mRNA decrease (LD av ) b| Wt KRAS (%) Responders (%)| NVPAEW541| 
Type 20 (334): t (%)| Referencea| [35S]GTP?•Rac1 (cpm) (% of control)| Recommended margins| Vesicle size| IGF-IR?:?IR-A| IGF-IR?:?IR-B| Iron-loaded rats| Tumor thickness| HARC Nef (6)| 
Type 21 (51): Functions in Membrane Trafficking| Ghrelin| GEP| Cell line derived from| targets and subjects| The anti-HCC effects| T3SS Description| common SE| Operation| Recommendations| 
Type 22 (76): Association with prognosis| Source of PCSCs| Clinical associations| WHO-EORTC| Hereditary breast and ovarian cancer syndrome| Effect in PCA| Sampling size| Oncogene classification according to their functions| Type of cell death| Outcome Measures| 
Type 23 (285): 10-CV| F344_Sal| Macrophages positive (%)| Probe set id| dbSNP 1| Number of aberrant crypt| IR6+FA| NgBR Score| %S| Reverse PDS (ATCCCT)| 
Type 24 (13): EPOR expression as PF (method)| Mode of actions/targets| Diagnosis (n)| Implementation| Gene/protein expression changes| PSTAIRE box sequence b (no. of substitutions)| Developmental stages investigated| Extracellular and Ligands| HUGO gene symbol| Sequences and location at 3?UTR of human CD44 mRNA| 
Type 25 (64): Table Name (Size)| Isoform targeted| Dose (range)| Green Label| Adapter molecules| DNA Analyzed| 3? Gene Information| Two-sample t-test| Responses to cytokines| Chromosome 3 gene symbols(CANDID score)| 
Type 26 (42): Microarrays plataform| Usual dose (daily unless mentioned)| Reported effect on ANRIL expression| Posttranslational| Single-agent erlotinib| IDF (2005)| Molecular characteristic| Compound (source)| GILZ effects| Gleason Score| 
Type 27 (125): Reverse Primer Sequence (5?-3?) [RP]| Primer sequences (5? to 3?)| Forward primer (5'...3')| Sequence 3| 3? GSP Sequence| Forward primers (5?–3?)| Primer Reverse (5'-->3')| Reverse primers (5?–3?)| Sense strand (5?->3?)| Sense probe (5?-3?)| 
Type 28 (40): Sizes (kDa, or disachharide)| MMTV-Wnt1/p53 +/-| Standard conditions| Disease and number*| Centrosome proteins| Position of peptide in the polypeptide chain| treatments| Moderately Resistant| GI>50 (?M ± SD)| NCBI CDD Hits| 
Type 29 (301): Control (n=8)| Loss of Stent| C40| CX3CL1 / Ki-67| Frequency (Percentage)| anti-P25 positive (%)| All mutations N(%)| 48 h OC| 40–56| Steroids| 
Type 30 (44): PATIENTS pre-treatment| Clinical applicability of PARP inhibition| Pfam Domain, Remarks| Screening Modes| Characteristicsa| Cell Types| Clinical association (References)| Effect on PML| Phenotype and latency (non-infected versus infected with M-MuLV)| GOTerm, DAVID-level3| 
Type 31 (128): Genbank Accession Numbers| Affymetrix gene| Clone accession no.| Name/ID| Search key| Assay code| GeneBank Accession #| IPI code| QIAGEN Cat. #| Trial #| 
Type 32 (678): Name| Pathway| Description| Protein name| Term| Cells| Category| Location| Cell type| Tumor type| 
Type 33 (70): information| Associated disease| Descriptive title| Cause of over and underexpression| Type of particles| Immune effector response| Type of alterations| Significant Pathway| Transplanted cells| Predicted function (from blast similarity)| 
Type 34 (74): Example(s)| Reaction class| Metastasis sites| Fraction number| Known or proposed functions| Model name| Injection/ Lens treatment| Source of Organisms| Known AS Event 2| Histology (WHO grade)| 
Type 35 (58): Sequencing strategy| Clusters a| Cluster (genes)| gene symbol, name and Entrez ID| 4th Key node| Dilution and incubation time| Study year| TBK1| PP1| Treatment at relapse| 
Type 36 (128): TNM *| Interventional scenario| Therapeutic Agent| 18| Immunotherapy group| Seed sequence| Candidate binding factor for TRE| Uniprot Accession| Traits 2| IRS Expression| 
Type 37 (46): Aim| Genes of cytochrome subunits| Family PDB chain| Form of Silk| miR-21 expression in human tissues/cells| MRI| Primary Endpoint(s)| Advanced Stage| Mast Cell Type/Origin| Gene Annotation| 
Type 38 (116): Mutation/ polymorphism| NS d| Name of the encoded protein| G1/S| Scenario name| STUDY| SAGE Libraries Used| Adjuvant systemic treatment c| Other toxicity| Sub-group| 
Type 39 (142): Cytoband| Start| Chromosome Location| chromosomal localization| Transcript ID| Selected Phosphomotifs showing strong interaction with GRB2 on peptide microarray| UM| Gene Location| Chr. Location| 6 h| 
Type 40 (32): Reverse primer sequence (5'?3')| 5?-sequence-3?| Reverse Primer 5?-3?| NCBI Accession number| Reverse (antisense) primer| Antisense primer sequence (5?–3?)| Reverse 5??3?| Human GenBank accession number Sequence 5?–3?| ???????? Reverse primers| ?????? Forward primers| 
Type 41 (84): Nucleotide Alteration| Neurocognition/Neuropathology| Paired Comparison| PPI subnetwork| Motif (BR)| TF Matrices| Profibrotic Signalling Pathways| MDR-related ABC transporters involved| FDR < 0.05| Toxin used| 
Type 42 (54): HT| Genes with increased regional number of detections| predicted to connect to gene(s)| Prostaglandin| peptide| Hub genes| CBM location| Diabetes/renal| Growth factors and cytokines| SYNDROME| 
Type 43 (867): Trematoda| 4c9z| ErbB4-KO| MIB-1| OBJECTIVE RESPONSE RATE (ORR) %| PSA before| 4ca1| Last fo low-up| WBC| Increase Fold in Treated Larva b| 
Type 44 (26): STAGE/PATIENTS| Address| Main BioPAX Classes Used| Oxysterols| Type of attenuator| Myeloma patients| Hormonal profile| INTERPRO term| ALK Alteration| Upregulated by IL-1?| 
Type 45 (100): Other Aliases| G4| HDAC Isoforms| gene(s)| Approach using HA-binding peptide| Character| Media VEGF Protein| Genes Identified in GO Terms| Sequenom's Assay Name| Virus Type, Name| 
Type 46 (1109): P value *| P *| SILAC ratio| difference| rho_tumor| WKY P -value| STD Rsk2 mutants| Similar regulation d| Homdel| Type III sum of squares| 
Type 47 (43): Putative Biomarkers| miR-Mask| Estradiol Regulated Genes| Genes Regulated and Underlying Mechanisms| Gene name (some shortened to fit)| Differentiation of groups| Herbal galactogogue| Cell Stimulus| Control Element Name| Coadministered drug and dosing regimen| 
Type 48 (158): Air| Net displacement (µm)±SD| Adjusted OR(95% CI) a| T3| Taqman Assay ID| ORhet(95%CI) b| Ever-smokers versus never-smokers| Fitted parameter q1 [ml O2/(105 cells min)]| Rectal prolapse (n=6)| 4–10| 
Type 49 (73): comments| 31| Subjects and approach| Working mechanism| Safety outcomes a| Recommended dose modification| Clonorchis sinensis predicted proteins (50,769) similar a to those in:| Functional Annotation| Kind of approach| Viral Agents| 
Type 50 (981): DA mimic| FD 3| Size (Bp)| L60/D| Protein size (amino acids)| pl| OD 260/280| Optimized UVB sites| # amino acids| #AAs| 
Type 51 (81): IPA| HOXA9?N| IC 50 a ( ? M)| M/F (%)| Fisher score b| RefSeq ID| PIK3CA mutation| Log 2 FC| Ref Seq| LBW Mean±SD| 
Type 52 (56): Inducer| Gene prediction| Diagnosis, subtype| Second antibody| Epigenetic regulation| Oxidant| Interaction effect| Effect for pathophysiology of renal injuries| Top Pfam hit| Top biological functions| 
Type 53 (411): Pediatric tumors targeted in studies| Cancer cell/tissue| Cancer site| Host| Mouse Homology| Tissue| Manufacturer| lineage conversion| Type of protein| Tissues| 
Type 54 (23): Arf 1hurA,B| Case 14| Genotyped samples| Case 3| RasGAP| Name of oligonucleotide| SNP a| SMO-Inhibitors| interacting DISC1 constructs| Percent (number)| 
Type 55 (25): Tumor + COX-2 siRNA State| Sequence of forward and reverse primers| Template structure (PDB accession code) #| Approach/Model| Label/time point| Incident of Genetic/Epigenetic Cell Cycle Alterations| cell type/intervention 1| cell type/intervention 2| Phase of experimentation| Experiment source scenario| 
Type 56 (24): Category name (Accession)| PTPN11 mutation| Drug (clinical trial sponsor)| Kinetic law| Recipient Mice*| Main oncogenic events| PPAR ? agonist + antitumor agent| Known Oncogenic Alterations| First name STUDY| Viral ECS-type ubiquitin ligases| 
Type 57 (6): Insert Gene| MEFs’ Genotype| Trial (ClinicalTrials.gov identifier)| Proteolytic cleavage sites| GENOTYPE| Description (UniGene cluster, GenBank accession no.)| 
Type 58 (149): Selected by EGFR positive| Tissue Type| Organ/tissue/cell type| Cancers| Compartment| 2. Extent of conformational change at the substrate site| Cancer or disease involved| Symptom| Cancer Examined| Cell/tissue type| 
Type 59 (49): Stage 11| Phyllanthus ?species| Df or mutation tested| Input signal| Secondary antibody| Radiosensitization| Prognostic indices/covariate model ( n )| Node2| Node1| CLO segment length| 
Type 60 (69): Representative homologous protein(s)| Domains a| Matrix protein coating concentration| Tumors/Injections Nude Mice (?T cells)| Author [reference]| Docking Score (kcal/mol)| Ras/Raf kinase/Extracellular Signal-Regulated Kinase (ERK) Pathway *| Study (year)| Clone (vender)| Dosage/duration/route| 
Type 61 (307): Effect of neuropeptide treatment on LH release in vivo| Rat parathyroid| Angiogenesis| Mets in animial| Newly Dx vs Progression| Enzyme Class| Activatory| Disease Group| Effect on IRES activity| Pham et al. [ 15 ]| 
Type 62 (22): Sequence c| Sequence (Probe: 5?-FAM- -TAMRA-3?)| reverse| ODN| modified peptide(s)| forward| Sense/Antisense: Sequences| Left primer| 5?-ACATCGCTCAGACACCATG-3?| Sequence of primer| 
Type 63 (163): AEG-1 expression| TFA| INPP4B expression| Cluster 2 (no.)| TFA+MSG| Hazard Ratio(95% CI)| PEGFR| Discovery set ( n =838), n (%)| Test set ( n =838)| Myc 5 ? -SAGE| 
Type 64 (180): T4| K+-free medium| ouabain| FA vs. TN| Pathway ID| Accession Number| Epigenetically regulated miRNAs| logFC| FVPTC vs. FA| miRs| 
Type 65 (15): Homologous Human Genomic Segment (Human Chromosome Number: From Base Pairs to Base Pairs)| cv-SMSE (0.05, 0.5,0.95 quantile)| Target scan's Context percentile/Mami score(in decimals)/miTG score ( in italics )| Supported by| Mapped Location on the Rat Genome (Rat Chromosome Number: From Base Pairs to Base Pairs)| Position [UMD 3.1]| LVI, n (%)| Affected amino acids| CI, n (%)| No. of Patients(Mean value of IGFBP-3 in ng/ml)| 
Type 66 (317): Hyphal length (µm) b| CRL5872 T/U| xmrk / kras| Log 2 ratio b| T 1/2 (h)| FC Pat. 9| Fold-Change (SI vs. SC)| LBFC| FC Pat. 6| FC Pat. 11| 
Type 67 (167): Methylation status and expression levels| No. of SNPs with p < 0.10 1| AO| R6| R7| R8| R9| Cyst with micropapillae| Number (%) MAGEA4 only| R10| 
Type 68 (54): Effects on HBV transcription and replication| Target name| Type of injury| Sequence (5??3?)a or description (Restriction sites are underlined)| Primary antibody incubation| Agent description| Synonyms, mouse| Data Types being Compared| Protein Identification| Processes(p-value)| 
Type 69 (148): BMP6 Meth| BMP3b Meth| SLiMPred score| Concurrent BMP3b and BMP6 Meth| Luteolin| HeLa| Btk ?/? Lyn ?/?| Transgenic| Leptin| Average velocity (?m/s)| 
Type 70 (350): Kinase| Primary target| Protein kinase| Molecule| Gene| Abbreviation| Signaling molecules| Gene ‡| Cellular target| Putative Gene Catalogs| 
Type 71 (48): mechanism| Model type| Effect of MEKi (10–0.3 µM) on Growth| Salivary gland| N2| miRNA target and its role in cancer| TaqMan assay ID| Psoriasis type| Sex of patients| Top Three Applications| 
Type 72 (1619): pEGFR| EGFR| E7 ( n =83)| Patient| Number of genes| Process and Gene| Grade| ESCC (n=27)| Number of cases| 2 h/1 h| 
Type 73 (57): Pathways and gene sets enriched by up-regulated genes| Discovery cohort size| Correlation with overall survival and outcome| Annotations| MGUS| Classical Analysis by GeneSifter| Differences compared to sporadic tumours| Description b (SGD)| Type of Peptide Evidence| Female Breast Cancer| 
Type 74 (36): Reverse| Forward primer| Reverse primer| Reverse Primer| Forward| Reverse primer (5?-3?)| Forward primer (5?-3?)| Sequence (5'-3')| Forward Primer| Sequence (5?-3?)| 
Type 75 (870):  | Response| Diagnosis| Method| Expression| (A)| Histology| Proliferation| Functionc| Experiment| 
Type 76 (302): Adenylyl cyclase activity (pmol of cAMP/mg/min) a| MS Mass| Time ?=?12h| rs11599672 (cases/controls)| ?Ct in qRT-PCR ( Mean ±SD)| No. of Cases /Controls| Significance (hypergeometric distribution)| GT counts controls| NCT protocol #| Apoptosis(%)| 
Type 77 (115): Proteina| Protein of F(K)| GPCR| UniProtKB| RTK| RefSeq RNA| Regulators of cell cycle| TGF-?1+ TNF-?| NEC Cell lines| Activated Molecules| 
Type 78 (32): Method for measuring ROS production| Molecular mechanisms of action| Example cases of Mutation disambiguation dictionary records and patterns| Gene Family| Gene symbol//gene title (ref #) – functional categories| Drug manufacturer| Epigenetic changes in CRC| Modeling Approach &Methodology| Used cells| Relevant properties| 
Type 79 (192): References| Reference| Breeding pairs| GDC-0941/PD0325901| HC-3| Refs| Flux (% Control)| NVP-BEZ235/PD0325901| References??| Et3Pb| 
Type 80 (625): Survival after biopsy (months)| MRNA levels| C/T fold change| wt-BRAF| September 2000| TTP (months)| this study| Numbers in COG| Fold change wt/ko qPCR| OS months| 
Type 81 (48): Complexes| DLT| Functional annotation by DAVID| Tumor selectivity| Targeting mechanism| Possible mechanisms of anti-HCC| Molecular target of ASO-based therapy| Perturbation| Identification of protein| Histological description| 
Type 82 (69): CSC culture conditions| Structural element| Pathogenetic Mechanism| Tumor cell line| Associate function| Annotation *| Related functions/pathways| Tissue or cell models| Cancer model| Strength of Evidence| 
Type 83 (45): Transfection reagent| Notes/Company| Substrates/targets| Tumor State| Viral Proteins| Protein names and Abbreviations| Description (GeneDB Annotation)| Developmental Stage| Proteasome inhibitor| Source scenario| 
Type 84 (46): Effects of the miR-34/chemo combination| Observation in PCOS| Parameters/Rat groups| Expression level and modification of Schwann cell proteins| Translocation effect| Dosing Regimen| Different categories| Activity/TCR-dependent signaling pathway| MSigDB annotation (Source)| REACTOME Pathways| 
Type 85 (40): Antitumor activity and/or mechanism| Human trials| nucleotide| miRNA regulation; validation method| Enzymes| Gene name of the ligand| Binding properties| Clinical development| Accession no. or reference| Vertebrates| 
Type 86 (554): ER+/PR+ cancer versus healthy| IMB| LOD score at ?| Recurrence-free survival (months)| DMD| Control vs. acid| Activated in PDS by Rph1 d| Log M (Diff expressed)| microarray| Abundance sks1-K39R b| 
Type 87 (115): Cellular processes| Gene Function| KEGG categories represented| KEGG subcategory| GO group| Biological function| GO Classification of Genes Up-regulated in Stat3 ?/? mice| Organ and injury| Phenotype investigated| Pathway/function| 
Type 88 (19): Circumstances| Seq description| Overlapping Significant Pathways| Approaches| Maintenance therapy| Disease or Syndrome| Initial therapy| Delivery system for modulation of miRNAs| Proteins with greater synthesis in HT29 cells| Reactome pathways downloaded| 
Type 89 (99): Common Names| Original function| Participants or cells/treatment| Nanosystem| High State in Sample| Animals, tissue, cells or SIRT1 activator| Accession Type| Mating yeast strain| tissue| Dietary Factors| 
Type 90 (184): Nogo-B| PHB copies [N (%)]| MGMT expression| pBADS136 protein expression| MSH2 expression| MLH1 expression| Issa 16 panel 1| Grade 1 to 2| miR-124 expression High (n%) Low (n%)| Discovery phase a| 
Type 91 (41): FACS, cerebral astrocytes*| FACS or otherwise identified cerebral neurons*+| Agents (dosage/day)| References/Methods| BCR-ABL construct| Wald ? 2 P -value (UK)| Generic Name| First author (reference)| Tie1 expression| Study ID| 
Type 92 (26): Growth Traits b| Num. of novel genes & stages where these are identified| Author and reference number| First AutorYear [Reference]| Tannin| Author (ref)| Estimated % Gene Space Sampled| Drug dose| REFs| Experimental Condition| 
Type 93 (26): Ras Proteins| Native peptide sequence| Nucleotide change a| Adenovirus| Length (composition)| Cell Phenotype| Array Platform| Primers used in real-time PCR| HUGO/MGI Symbol| ArrayExpress or GEO accession| 
Type 94 (13): Rev Primer Seq| Fwd Primer Seq| Mature miR sequence| Predicted Mature miRNA *| Right Primer| Oligonucleotide Primers| Sequence (5?- 3?)| Forward Primer (5??3?)| Primers for RT-PCR| Primers for ChIP| 
Type 95 (26): Relevant Gene Ontology Biological or Molecular Designations| Functions of non-septins| Biological consequence| Medicinal properties| Iron compounds| Ab type| TALEs| Biological function(s)| Combination Agents| Plasma protein| 
Type 96 (47): Duration of post-transplantation experiments| Gene Description:| Incubation time and temperature| Pros| Genetic aberration| Tumor latency| Official gene symbol| Tumors (estimated penetrance)| Enzyme description (name)| Source of lung cancer specimen| 
Type 97 (135): HOPX expression| Role/Function| Method of analyses| Clinical trial number (adult)| Conseuence| Expressing tumor type| GO categories| Measurements| Mushroom species| Mutations induced in E.coli only (%)| 
Type 98 (436): Adverse event| Clinicopathological Features| Phytochemical| Clinicopathological variables a| Patients characteristics| Characteristic at initial diagnosis| cellular localization| Orientation| Functional Group| Mammary tumor| 
Type 99 (123): Flux per cell volume versus proliferation rate| K i, nM a| Core Haplotype Frequencies| DRI values (mean±s.e.)| N a| Bcl-2/Bax| LA| P - value| IC 50 ( ? M )| Tumor size| 
